Mosunetuzumab in combination with CHOP in previously untreated DLBCL: safety and efficacy results from a phase 2 study

Up to 40% of patients with diffuse large B-cell lymphoma (DLBCL) are refractory to or relapse after first-line therapy, highlighting the need for better treatments. Mosunetuzumab is a CD20 × CD3 bispecific antibody that engages and redirects T cells to eliminate malignant B cells. In this phase 2, o...

Descripción completa

Detalles Bibliográficos
Autores principales: Olszewski, Adam J., Phillips, Tycel J., Hoffmann, Marc S., Armand, Philippe, Kim, Tae Min, Yoon, Dok Hyun, Mehta, Amitkumar, Greil, Richard, Westin, Jason, Lossos, Izidore S., Munoz, Javier L., Sit, Jason, Wei, Michael C., Yang, Annie, Chen, Vivian, Purev, Enkhtsetseg, Yee, Donald L., Jaeger, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Immunobiology and Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582312/
https://www.ncbi.nlm.nih.gov/pubmed/37581593
http://dx.doi.org/10.1182/bloodadvances.2023010840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582312/
https://www.ncbi.nlm.nih.gov/pubmed/37581593
http://dx.doi.org/10.1182/bloodadvances.2023010840

Ejemplares similares